Myeov Inhibitors
Chemical inhibitors of Myeov can exert their inhibitory effects through interference with key signaling pathways that Myeov relies on for its functional roles in cellular processes. GW5074, by targeting Raf-1 kinase within the MAPK/ERK pathway, can disrupt the downstream signaling that Myeov enhances, particularly in cellular invasion processes. Similarly, PD0325901 and AZD6244 (Selumetinib) both inhibit MEK1/2, crucial kinases in the MAPK pathway, thus impeding the pathway's activation and the subsequent involvement of Myeov in related cellular events. U0126 also targets MEK1/2, offering another avenue for inhibiting the ERK pathway and consequently Myeov's function. Sorafenib, through its multi-kinase inhibition, including several RAF kinases, can impair the MAPK signaling and inhibit the activity of Myeov.
Additionally, SP600125 impedes the JNK pathway, which plays a role in cellular proliferation and survival where Myeov is implicated. By inhibiting JNK, SP600125 can disrupt Myeov's contribution to these cellular processes. SB203580, a p38 MAPK inhibitor, can obstruct the stress and inflammatory cytokine pathways where Myeov may be functionally involved, leading to its inhibition. For the PI3K/AKT pathway, both LY294002 and Wortmannin serve as inhibitors, thereby preventing the pathway's activation and disrupting Myeov's role in mediating cellular processes such as growth and survival. Rapamycin, an mTOR inhibitor, further inhibits the PI3K/AKT pathway downstream, leading to the inhibition of Myeov's function in cell growth and proliferation. Lastly, Dasatinib and PP2, as Src kinase inhibitors, can impede the Src kinase-related signaling pathways, thereby inhibiting the functional role of Myeov within these pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a selective inhibitor of Raf-1 kinase, which is a part of the MAPK/ERK pathway. Myeov is known to enhance cancer cell invasion through the MAPK/ERK pathway, so inhibition of Raf-1 kinase by GW5074 can lead to a reduction in Myeov-mediated cellular invasion processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the signaling pathways that affect cellular proliferation and survival where Myeov is implicated. Inhibition of JNK can therefore inhibit the functional contribution of Myeov to these cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K/AKT pathway is crucial for multiple cellular processes, including those influenced by Myeov. Inhibition of PI3K can interrupt the signaling cascade that Myeov might participate in, leading to functional inhibition of Myeov's role in these processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are kinases in the MAPK/ERK pathway. By inhibiting MEK, U0126 can impede the pathway's activation, thereby inhibiting Myeov's involvement in ERK pathway-mediated cellular events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, this compound can inhibit the pathways that are activated by stress and inflammatory cytokines where Myeov may play a role, leading to the inhibition of Myeov's functional involvement in these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, which is a part of the PI3K/AKT pathway, Rapamycin can lead to the functional inhibition of Myeov by disrupting the pathway that Myeov utilizes for promoting cell growth and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which can effectively inhibit the PI3K/AKT signaling pathway. Inhibition of this pathway can lead to the functional inhibition of Myeov by preventing its role in cellular processes mediated by this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several RAF kinases and receptor tyrosine kinases involved in MAPK signaling. Through these inhibitions, Sorafenib can functionally inhibit the activity of Myeov which is associated with the MAPK pathway. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
AZD6244, also known as Selumetinib, is an inhibitor of MEK1/2. As Myeov is implicated in MAPK pathway signaling, inhibition of MEK1/2 by AZD6244 can functionally inhibit Myeov's associated cellular roles. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor. Since Myeov is associated with pathways that involve Src kinase activity, inhibition of Src by Dasatinib can lead to the inhibition of Myeov's function in those pathways. | ||||||